再鼎醫藥(09688.HK)Bemarituzumab獲國家藥品審評中心突破性治療認定
再鼎醫藥(09688.HK)(ZLAB.US)宣佈,旗下FPA144注射液(bemarituzumab)獲國家藥品審評中心授予突破性治療認定,改良FOLFOX6化療方案聯用,一線治療FGFR2b過表達、HER2陰性的局部晚期/轉移性胃及胃食管交界部癌的患者。
再鼎醫藥總裁、腫瘤領域全球開發負責人Alan Sandler表示,很高興看到Bemarituzumab與化療聯用,作爲一線治療在晚期胃癌或胃食管交界部癌患者的關鍵終點上展現出具有臨牀意義的治療效果,將積極配合註冊部門工作,推動其進入全球註冊研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.